Cholesterol hydrophobically modified chitosan (CS-CH) containing 1.7–4.7 cholesterol
groups per 100 anhydroglucosamine units of chitosan were synthesized by an EDC …

Present limitations in the management of extraocular diseases include the inability to
provide long-term extraocular drug delivery without compromising intraocular structures …

Abstract Development of efficient ocular delivery nanosystems remains a major challenge to
achieve sustained therapeutic effect. The purpose of this work was to develop chitosan …

Purpose. To assess the potential of chitosan (CS) nanoparticles for ocular drug delivery by
investigating their interaction with the ocular mucosa in vivo and also their toxicity in …

The topical application of ophthalmic drugs is a convenient and safe mode of drug
administration. However, the bioavailability of topical drugs in the eye is low due to eye …

Purpose: To characterize nanoparticles produced by self-assembly of oppositely charged
polymers, cationic chitosan (CS), and anionic dextran sulfate (DS), for drug delivery to the …

The aim of this study was to develop cyclosporine A (CsA) loaded solid lipid nanoparticles
(SLN) associated with chitosan (CS), to improve interaction and internalization in corneal …

The present study aimed to develop and optimize chitosan coated solid lipid nanoparticles
(chitosan-SLNs) encapsulated with methazolamide. Chitosan-SLNs were successfully …

This study is focused on further understanding the characteristics of chitosan-N-
acetylcysteine surface-modified nanostructured lipid carriers (CS-NAC-NLCs) in their …

In the present study, cyclosporine A (CsA) was successfully incorporated into cationic
chitosan nanoparticles by spray-drying method aiming ocular application. Physicochemical …